Histologic evaluation of metastases in renal cell carcinoma with sarcomatoid transformation and its implications for systemic therapy.
about
Targeted therapies and the treatment of non-clear cell renal cell carcinomaPAX-8 expression in renal tumours and distant sites: a useful marker of primary and metastatic renal cell carcinoma?Percentage of sarcomatoid component as a prognostic indicator for survival in renal cell carcinoma with sarcomatoid dedifferentiation.Sarcomatoid renal cell carcinoma: a comprehensive review of the biology and current treatment strategies.Impact of pathological tumour characteristics in patients with sarcomatoid renal cell carcinomaGenomic characterization of sarcomatoid transformation in clear cell renal cell carcinoma.Biphasic components of sarcomatoid clear cell renal cell carcinomas are molecularly similar to each other, but distinct from, non-sarcomatoid renal carcinomasSystemic therapy for sarcomatoid renal cell carcinoma.Insights into cancer metastasis from a clinicopathologic perspective: Epithelial-Mesenchymal Transition is not a necessary step.Clinical outcome of high-dose bolus intravenous interleukin-2 with a modified administration schedule for Asian patients with metastatic renal cell carcinoma.Limitations of preoperative biopsy in patients with metastatic renal cell carcinoma: comparison to surgical pathology in 405 cases.The Role of Metastasectomy in Patients with Renal Cell Carcinoma with Sarcomatoid Dedifferentiation: A Matched Controlled Analysis.Unusual early-stage pancreatic sarcomatoid carcinoma.Outcomes of Patients with Renal Cell Carcinoma and Sarcomatoid Dedifferentiation Treated with Nephrectomy and Systemic Therapies: Comparison between the Cytokine and Targeted Therapy Eras.Ki-67 index and percentage of sarcomatoid differentiation were two independent prognostic predictors in sarcomatoid renal cell carcinoma
P2860
Q26995391-B90C0DC5-4979-4C0A-90C4-5CAAB158A8F5Q35598471-D410C2FC-5464-463E-9250-D2094312117CQ35640244-BB03938A-CEEA-4328-BCC5-87DDE8DEF639Q35705266-41C42ED9-1788-4779-9EAB-9EA30A9D8630Q36365688-21D98939-C7CA-4E8A-B391-5F6284660EEDQ36646352-2F426999-87CA-46D0-AC4B-10772B112C69Q37082565-526F5FBD-9D5E-477B-9549-A8CDA6B6AA36Q37894680-6F954768-786B-45B8-916D-90ED0C919633Q38029555-6C18CC30-EB10-4355-B9ED-6029D04DDA47Q39067371-50AAEA69-EB6A-4714-B684-451DFC286844Q39629310-4C9E39B3-BD68-4ADE-A5C1-B096EA987EC2Q41036577-24B8947A-3C37-4625-839C-494126C9ADEEQ41873064-2E5A8060-5279-43BE-9D60-88C69EC54128Q52776777-9E26F482-FFA6-4DF2-A999-2C0CDB53ED5EQ59135034-15213661-C12C-4402-9539-F4DC29E51AC2
P2860
Histologic evaluation of metastases in renal cell carcinoma with sarcomatoid transformation and its implications for systemic therapy.
description
2010 nî lūn-bûn
@nan
2010 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Histologic evaluation of metas ...... ications for systemic therapy.
@ast
Histologic evaluation of metas ...... ications for systemic therapy.
@en
type
label
Histologic evaluation of metas ...... ications for systemic therapy.
@ast
Histologic evaluation of metas ...... ications for systemic therapy.
@en
prefLabel
Histologic evaluation of metas ...... ications for systemic therapy.
@ast
Histologic evaluation of metas ...... ications for systemic therapy.
@en
P2093
P2860
P356
P1433
P1476
Histologic evaluation of metas ...... ications for systemic therapy.
@en
P2093
Allan J Pantuck
Arie S Belldegrun
Brian Shuch
Fairooz F Kabbinavar
Frederic Pouliot
Jeffrey C LaRochelle
Jonathan Said
Tobias Klatte
P2860
P304
P356
10.1002/CNCR.24768
P407
P577
2010-02-01T00:00:00Z